## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_20 at 12.1% exceeds exhaustion threshold (10.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops. Caution: momentum weakening (-16.1% MRS).

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($57.73)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_20 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given New $100.00 Price Target at Piper Sandler**
- Source: MarketBeat | 20251217T140857 | Bullish | Relevance: 100%
- Piper Sandler has increased its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $100 from $70, maintaining an "overweight" rating and suggesting a significant upside. This move comes amidst mixed analyst ratings but follows several other price target increases. Insider selling activity, including a large sale by CEO Christopher Anzalone, has also been noted.

**2. Piper Sandler Raises Arrowhead Pharma (ARWR) Price Target to $100 | ARWR Stock News**
- Source: GuruFocus | 20251217T130857 | Bullish | Relevance: 100%
- Piper Sandler has increased its price target for Arrowhead Pharma (ARWR) to $100 from $70, while maintaining an "Overweight" rating. This 42.86% increase reflects a positive outlook, supported by other analysts who have also raised their price targets for the biotechnology company focused on genetic disease treatments. Despite this, the average analyst target suggests a slight downside from its current price, and GuruFocus estimates indicate a potential downside in fair value.

**3. Piper Sandler raises Arrowhead Pharma stock price target to $100 on Redemplo launch**
- Source: Investing.com India | 20251217T130857 | Bullish | Relevance: 100%
- Piper Sandler has increased its price target for Arrowhead Pharmaceuticals (NASDAQ:ARWR) to $100 from $70, maintaining an Overweight rating and naming it a "Top Pick for 2026" due to the Redemplo launch and upcoming SHTG data. The firm projects significant sales for Redemplo following its launch for Familial Chylomicronemia Syndrome (FCS) and anticipates positive Phase III data for severe hypertriglyceridemia (SHTG) in Q3 2026, which could lead to "blockbuster label expansion." This positive outlook is further supported by Arrowhead's strong cash position and additional pipeline developments, reflecting a confident analyst sentiment despite recent varying price targets from other firms.

**4. Arrowhead Pharmaceuticals (ARWR) Stock Drops on Dec. 16, 2025: Latest News, Analyst Forecasts, and What Investors Are Watching**
- Source: ts2.tech | 20251216T180857 | Neutral | Relevance: 99%
- Arrowhead Pharmaceuticals (ARWR) experienced a significant stock drop on December 16, 2025, falling about 9% after reaching an intraday low of $59.76. This pullback is attributed to profit-taking following a strong run-up tied to recent regulatory successes, including FDA approval for REDEMPLO, a Breakthrough Therapy designation for plozasiran, and the initiation of an Alzheimer's-related clinical program. Despite the drop, analysts' price targets are generally rising, reflecting the company's transition to a commercial-stage biotech with significant pipeline potential, albeit with inherent market volatility.

**5. Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Down 7.6% - What's Next?**
- Source: MarketBeat | 20251216T172336 | Somewhat-Bearish | Relevance: 95%
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares dropped 7.6% during Tuesday's mid-day trading. Despite a "Moderate Buy" consensus from analysts with several firms raising price targets, the stock saw reduced trading volume and insider selling totaling approximately $2.19 million over the past 90 days. Institutional investors, led by Vanguard, hold a significant stake in the company.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-17 | Piper Sandler | $100 | $70 | +43% |
| 2025-12-11 | RBC Capital | $80 | $52 | +54% |
| 2025-12-09 | B of A Securiti | $81 | $62 | +31% |
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-17 | Piper Sandler | main | Overweight |
| 2025-12-11 | RBC Capital | main | Outperform |
| 2025-12-09 | B of A Securiti | main | Buy |
| 2025-12-02 | HC Wainwright & | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 3 ($2.19M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-16.1% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (11.3%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 9 raises (avg +37%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -27% YoY, concerning. Analyst sentiment positive (9 raises, avg +37%). Insider selling cluster ($2.2M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.2B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 11.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 28.2% to 12.1% (-16.1% in 5 days), indicating relative weakness vs NASDAQ. Extended beyond STRENGTH zone (12.1% > 10.0%), caution on chasing. MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 11.1% shows strong absolute momentum above own 20MA. Outperforming sector by 11.7pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). OFD pattern: +SLL (Support).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 12.09% (CS: 98) | Strong |
| RSI_14 | 65.8 | Neutral |
| MACD Histogram | -0.32 | Bearish |
| vs SMA20 | 1.111x | Above |
| vs SMA50 | 1.403x | Above |
| vs SMA200 | 2.579x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $66.47
- **Stop Loss:** $57.73 (13.1% risk)
- **Target:** $75.21 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 108
- **Position Value:** $7,178.76
- **Portfolio %:** 7.18%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*